K2 Therapeutics
Singapore-based biotech founded by MPM BioImpact in 2024 that sources first- and best-in-class drug candidates globally and develops them in-house through a hub-and-spoke model; the $50M seed supports a portfolio of eight programs spanning ADCs, bispecific T-cell engagers and cell therapy, with disclosed programs including KTT-001, a PRAME-targeted cell therapy for solid tumors.
Headquarters
Singapore
Year Founded
2024
Founders
Founded by MPM BioImpact; Ying Huang (CEO since 2026), Frank Neumann (CMO)
Country
Singapore
Financial Information
Funding Stage
Seed
Recent Funding
$50M
Funding By
MPM BioImpact
Core Technology
Hub-and-spoke development engine sourcing assets across modalities and geographies
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: In-licensed assets under a global sourcing model
Partnerships
Pharma Collaborations
MPM BioImpact (founder and sole seed investor)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
Not disclosed
Market & Differentiation
Cross-regional development of in-licensed assets with disciplined, portfolio-scale execution